NHI reimbursement approved MSD's Syprine

Published: 2006-03-23 06:56:00

Updated: 2006-03-23 06:56:00

MSD Korea has obtained the NHI reimbursement approval for Syprine (trientine hydrochloride) for the treatment of Wilson's disease, a rare disease, under the tradename of "MSD trientine" effective from Feb. 1. Syprine was registered as an orphan drug in 2005, which has been classified as a common ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK